Product Name: Nerinetide
CAS No: 500992-11-0
Purity: 95%
Molar Mass: 2518.88
Chemical Formula: C105H188N42O30
Synonyms: Nerinetide, NA-1
Storage: Store at -20℃
Sequence: YGRKKRRQRRRKLSSIESDV
Target: NMDA Receptor, nNOS
Application: Nerinetide (CAS: 500992-11-0) presents a groundbreaking opportunity in acute ischemic stroke treatment by addressing critical pathways involved in post-stroke neuronal injury and cell death. Through its unique mechanism, nerinetide intervenes in the interaction between postsynaptic density protein-95 (PSD-95) and the N-methyl-D-aspartate (NMDA) receptor, effectively mitigating excitotoxicity, a primary contributor to neuronal damage following ischemic stroke. Excitotoxicity arises from the excessive influx of calcium ions into neurons, triggering a cascade of events leading to cell death. By blocking the PSD-95/NMDA receptor interaction, nerinetide curtails this cascade, preserving neuronal integrity and function, particularly in the ischemic penumbra, the region surrounding the core infarct where salvageable tissue exists. Preclinical investigations have shown promising results, demonstrating nerinetide’s ability to reduce infarct size, improve neurological outcomes, and enhance long-term functional recovery in animal models of ischemic stroke. Building upon these findings, early-phase clinical trials have provided encouraging insights into nerinetide’s safety and potential efficacy in human stroke patients. These trials have highlighted its favorable safety profile and early indications of neuroprotective effects, positioning nerinetide as a promising adjunctive therapy to existing treatments. The development of nerinetide signifies a significant advancement in stroke care, offering a targeted approach to neuroprotection that addresses the intricate pathophysiology of ischemic stroke. If successful in larger-scale clinical trials, nerinetide could emerge as a transformative therapeutic option for acute ischemic stroke patients, complementing standard treatments such as thrombolytic therapy and mechanical thrombectomy. By preserving neuronal function and limiting brain injury, nerinetide has the potential to improve clinical outcomes, reduce disability, and revolutionize acute ischemic stroke management on a global scale. Ongoing research efforts continue to explore nerinetide’s therapeutic potential and optimize its clinical utility in stroke care. Through rigorous clinical evaluation and further elucidation of its mechanisms of action, nerinetide aims to fulfill its promise as a game-changing intervention in the battle against acute ischemic stroke, a leading cause of morbidity and mortality worldwide.
Reference:
